Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V920 Ebola Vaccine in Healthy Adults
NCT02280408Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Dec 2015
- Modality
- Viral Vector Vaccines
01
Overview
Phase 1, randomised, double-blind trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With 1 or More Unsolicited AE, Percentage of Participants With 1 or More Solicited Systemic Adverse Event (AE) by Severity and 3 more. Started Oct 2014; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02280408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280408.